Figures
There are errors in the formatting of Figure 3 and Table 4.
Results are expressed from the respective main dose results of the phase 3 trials [1]–[5] in the intent-to-treat analysis for efficacy (Stroke and systemic embolism, ischemic stroke) and in the safety analysis for intracranial hemorrhage. AP, apixaban; BID, twice-daily dosing; CE, common estimate; CI, confidence interval; DE, dabigatran etexilate; EDOX, edoxaban; HR, hazard ratio; QD, once-daily dosing; RIVA, rivaroxaban; SE, systemic embolism; W, warfarin; aIn the ROCKET-AF trial, only ischemic strokes, excluding unspecified strokes, are reported. Note: bold and italic font marks significantly superior results.
Please see the corrected Figure 3 here.
Please see the corrected Table 4 here.
Reference
Citation: The PLOS ONE Staff (2014) Correction: Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria. PLoS ONE 9(9): e109437. https://doi.org/10.1371/journal.pone.0109437
Published: September 26, 2014
Copyright: © 2014 The PLOS ONE Staff. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.